keyword
https://read.qxmd.com/read/38597325/adamts13-deficiency-exacerbates-neuroinflammation-by-targeting-matrix-metalloproteinase-9-in-ischemic-brain-injury
#1
JOURNAL ARTICLE
Hongxiang Jiang, Juntao Hu, Peidong He, Yu Wu, Fei Li, Qianxue Chen
Our design aimed to explore the potential involvement of matrix metalloproteinase-9 (MMP-9) in the inflammatory response associated with acute ischemic stroke (AIS). We also aimed to preliminarily examine the potential impact of a disintegrin-like and metalloprotease with thrombospondin type I repeats-13 (ADAMTS13) on MMP-9 in AIS. We conducted oxygen-glucose deprivation models of microglia cells and mice models of AIS with middle cerebral artery occlusion (MCAO). We assessed the expression pattern of MMP-9 with western blotting (WB) and real-time quantitative PCR both in vivo and in vitro...
May 8, 2024: Neuroreport
https://read.qxmd.com/read/38583954/angiotensin-ii-is-involved-in-mlkl-activation-during-the-development-of-heart-failure-following-myocardial-infarction-in-rats
#2
JOURNAL ARTICLE
Tetsuro Marunouchi, Sumika Onda, Minami Kurasawa, Kouichi Tanonaka
Several reports assume that myocardial necroptotic cell death is induced during the development of chronic heart failure. Although it is well accepted that angiotensin II induces apoptotic cell death of cardiac myocytes, the involvement of angiotensin II in the induction of myocardial necroptosis during the development of heart failure is still unknown. Therefore, we examined the role of angiotensin II in myocardial necroptosis using rat failing hearts following myocardial infarction and cultured cardiomyocytes...
2024: Biological & Pharmaceutical Bulletin
https://read.qxmd.com/read/38284173/the-impact-of-phosphodiesterase-5-inhibition-or-angiotensin-converting-enzyme-inhibition-on-right-and-left-ventricular-remodeling-in-heart-failure-due-to-chronic-volume-overload
#3
JOURNAL ARTICLE
Tereza Tykvartova, Matus Miklovic, Martin Kotrc, Petra Skaroupkova, Ludmila Kazdova, Jaroslava Trnovska, Vojtech Skop, Michal Kolar, Jiri Novotny, Vojtech Melenovsky
While phosphodiesterase-5 inhibition (PED5i) may prevent hypertrophy and failure in pressure-overloaded heart in an experimental model, the impact of PDE5i on volume-overload (VO)-induced hypertrophy is unknown. It is also unclear whether the hypertrophied right ventricle (RV) and left ventricle (LV) differ in their responsiveness to long-term PDE5i and if this therapy affects renal function. The goal of this study was to elucidate the effect of PDE5i treatment in VO due to aorto-caval fistula (ACF) and to compare PDE5i treatment with standard heart failure (HF) therapy with angiotensin-converting enzyme inhibitor (ACEi)...
February 2024: Pharmacology Research & Perspectives
https://read.qxmd.com/read/38236117/melanoma-and-dysplastic-nevi-development-after-ranitidine-rilmenidine-%C3%B0-oxonidine-lercanidipine-rosuvastatin-and-verapamil-trandolapril-new-data-case-series-the-potential-role-of-nitrosamine-ndsris-contamination-in-polymedication-as-substantial-skin-cancer
#4
JOURNAL ARTICLE
G Tchernev, N Naydekova
The idea of drug-induced/exogenic Nitrosogenesis is driven by the possibility of prolonged exposure of the human body to the influence of nitrosamines within the drug intake - substances or contaminants that have been proven to be carcinogenic or mutagenic one.Until recently, there was a complete lack of data in the scientific literature on the relationship between cancer, polymedication and polycontamination with nitrosamines. In the last decade, melanoma has been described repeatedly in the medical literature as a possible side-effect within the intake of possibly with nitrosamines contaminated medications such as: Valsartan, Hydrochlorothiazide, Amlodipine, Nebivolol, Bisoprolol and Perindopril...
November 2023: Georgian Medical News
https://read.qxmd.com/read/38078460/the-association-between-ace-inhibitors-and-psoriasis-based-on-the-drug-targeted-mendelian-randomization-and-real-world-pharmacovigilance-analyses
#5
JOURNAL ARTICLE
Qiubai Jin, Feihong Ren, Ping Song
BACKGROUND: Although a growing number of observational studies suggest that angiotensin-converting enzyme inhibitors (ACEIs) intake may be a risk factor for psoriasis, evidence is still insufficient to draw definitive conclusions. RESEARCH DESIGN AND METHODS: Drug-targeted Mendelian randomization (DTMR) was used to analyze the causality between genetic proxied ACEIs and psoriasis. Furthermore, we performed a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database to identify more suspicious subclasses of ACEIs...
December 11, 2023: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38017033/the-treatment-with-trandolapril-and-losartan-attenuates-pressure-and-volume-overload-alternations-of-cardiac-connexin-43-and-extracellular-matrix-in-ren-2-transgenic-rats
#6
JOURNAL ARTICLE
Matus Sykora, Vojtech Kratky, Ludek Cervenka, Libor Kopkan, Narcis Tribulova, Barbara Szeiffova Bacova
Heart failure (HF) is life-threatening disease due to electro-mechanical dysfunction associated with hemodynamic overload, while alterations of extracellular matrix (ECM) along with perturbed connexin-43 (Cx43) might be key factors involved. We aimed to explore a dual impact of pressure, and volume overload due to aorto-caval fistula (ACF) on Cx43 and ECM as well as effect of renin-angiotensin blockade. Hypertensive Ren-2 transgenic rats (TGR) and normotensive Hannover Sprague-Dawley rats (HSD) that underwent ACF were treated for 15-weeks with trandolapril or losartan...
November 27, 2023: Scientific Reports
https://read.qxmd.com/read/37466151/angiotensin-converting-enzyme-inhibitors-and-angiotensin-receptor-blockers-for-adults-with-early-stage-1-to-3-non-diabetic-chronic-kidney-disease
#7
REVIEW
Tess E Cooper, Claris Teng, David J Tunnicliffe, Brydee A Cashmore, Giovanni Fm Strippoli
BACKGROUND: Chronic kidney disease (CKD) is a long-term condition that occurs as a result of damage to the kidneys. Early recognition of CKD is becoming increasingly common due to widespread laboratory estimated glomerular filtration rate (eGFR) reporting, raised clinical awareness, and international adoption of the Kidney Disease Improving Global Outcomes (KDIGO) classifications. Early recognition and management of CKD affords the opportunity to prepare for progressive kidney impairment and impending kidney replacement therapy and for intervention to reduce the risk of progression and cardiovascular disease...
July 19, 2023: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/37417783/angiotensin-converting-enzyme-inhibitor-induced-cough-compared-with-placebo-and-other-antihypertensives-a-systematic-review-and-network-meta-analysis
#8
JOURNAL ARTICLE
Yiyun Hu, Ling Liang, Shuang Liu, Janice Y Kung, Hoan Linh Banh
Studies have shown that angiotensin converting enzyme inhibitors (ACEIs) are superior in primary and secondary prevention for cardiac mortality and morbidity to angiotensin receptor blocker (ARBs). One of the common side effects from ACEI is dry cough. The aims of this systematic review, and network meta-analysis are to rank the risk of cough induced by different ACEIs and between ACEI and placebo, ARB or calcium channel blockers (CCB). We performed a systematic review, and network meta-analysis of randomized controlled trials to rank the risk of cough induced by each ACEI and between ACEI and placebo, ARB or CCB...
August 2023: Journal of Clinical Hypertension
https://read.qxmd.com/read/37149094/in-silico-and-in-vitro-screening-for-carcinogenic-potential-of-angiotensin-converting-enzyme-inhibitors-and-their-degradation-impurities
#9
JOURNAL ARTICLE
Katarzyna Regulska, Agnieszka Matera-Witkiewicz, Aleksandra Mikołajczyk, Beata J Stanisz
According to some clinical observations, the use of angiotensin-converting enzyme inhibitors (ACEI) may be associated with an increased risk of cancer. The aim of the present study was to screen for the potential carcinogenicity, mutagenicity and genotoxicity of these drugs using in silico methodology. Delapril, enalapril, imidapril, lisinopril, moexipril, perindopril, ramipril, trandolapril, spirapril were thereby analyzed. In parallel, the corresponding degradation impurities, the diketopiperazine (DKP) derivatives, were also investigated...
May 4, 2023: Toxicology and Applied Pharmacology
https://read.qxmd.com/read/36204993/endothelin-type-a-receptor-blockade-attenuates-aorto-caval-fistula-induced-heart-failure-in-rats-with-angiotensin-ii-dependent-hypertension
#10
JOURNAL ARTICLE
Petr Kala, Olga Gawrys, Matúš Miklovič, Zdenka Vaňourková, Petra Škaroupková, Šárka Jíchová, Janusz Sadowski, Elzbieta Kompanowska-Jezierska, Agnieszka Walkowska, Josef Veselka, Miloš Táborský, Hana Maxová, Ivana Vaněčková, Luděk Červenka
OBJECTIVE: Evaluation of the effect of endothelin type A (ETA) receptor blockade on the course of volume-overload heart failure in rats with angiotensin II-dependent hypertension. METHODS: Ren-2 renin transgenic rats (TGR) were used as a model of hypertension. Heart failure was induced by creating an aorto-caval fistula (ACF). Selective ETA receptor blockade was achieved by atrasentan. For comparison, other rat groups received trandolapril, an angiotensin-converting enzyme inhibitor (ACEi)...
October 5, 2022: Journal of Hypertension
https://read.qxmd.com/read/36027189/inhibition-of-ras-components-attenuates-progression-of-myocardial-remodeling-in-both-normotensive-and-hypertensive-rats-in-experimental-heart-failure
#11
JOURNAL ARTICLE
Matus Sykora, Vojtech Kratky, Narcis Tribulova, Libor Kopkan, Barbara Szeiffova Bacova
OBJECTIVE: New findings in the pathogenesis of heart failure (HF) with a focus on extracellular matrix (ECM) and communication in the heart are still relevant for more effective treatment. We focused on signaling pathways involved in cardiac structural remodeling in HF due to pressure and volume overload, as well as on investigating the efficacy of substances with possible antifibrotic potential. DESIGN AND METHOD: We used as experimental model 28-week-old hypertensive (TGR) and normotensive (HSD) rats with created aortocaval fistula (ACF), supplemented with ACE inhibitor (ACEi) (Trandolapril, 15 weeks, 6 mg/L) and AT1 receptor blocker (ARB) (Losartan, 15 weeks, 200 mg/L)...
June 1, 2022: Journal of Hypertension
https://read.qxmd.com/read/34884209/angioedema-caused-by-drugs-that-prevent-the-degradation-of-vasoactive-peptides-a-pharmacovigilance-database-study
#12
JOURNAL ARTICLE
Yoshihiro Noguchi, Azusa Murayama, Hiroki Esaki, Mayuko Sugioka, Aisa Koyama, Tomoya Tachi, Hitomi Teramachi
Angioedema results from the decreased degradation of vasoactive peptides such as substance P and bradykinin. In this study, we sought to clarify whether dipeptidyl peptidase-4 (DPP-4) and angiotensin-converting enzyme (ACE) inhibitors that suppress the degradation of substance P and bradykinin are involved in angioedema onset. We calculated information coefficients (ICs) by performing a disproportionality analysis to evaluate DPP-4/ACE inhibitor-induced angioedema using the Japanese Adverse Drug Event Report (JADER) database...
November 25, 2021: Journal of Clinical Medicine
https://read.qxmd.com/read/34567875/once-versus-twice-daily-angiotensin-converting-enzyme-inhibitors-for-blood-pressure-control-in-adult-patients-with-hypertension
#13
REVIEW
Kyle Fischer, Sandy Diec
This review aimed to assess the efficacy and safety of once- versus twice-daily administration of angiotensin-converting enzyme (ACE) inhibitors for the management of hypertension. A literature search on PubMed and Google Scholar was performed (January 1980 to June 2020) using the following search terms: ACE inhibitors, lisinopril, enalapril, fosinopril, trandolapril, ramipril, perindopril, captopril, benazepril, ambulatory blood pressure, hypertension, twice-daily dosing, once-daily dosing. Reference lists from retrieved articles were examined for additional reports...
August 2021: Curēus
https://read.qxmd.com/read/34566652/effects-of-trandolapril-on-structural-contractile-and-electrophysiological-remodeling-in-experimental-volume-overload-heart-failure
#14
JOURNAL ARTICLE
Dagmar Jarkovská, Matúš Miklovič, Jitka Švíglerová, Luděk Červenka, Petra Škaroupková, Vojtěch Melenovský, Milan Štengl
Chronic volume overload induces multiple cardiac remodeling processes that finally result in eccentric cardiac hypertrophy and heart failure. We have hypothesized that chronic angiotensin-converting enzyme (ACE) inhibition by trandolapril might affect various remodeling processes differentially, thus allowing their dissociation. Cardiac remodeling due to chronic volume overload and the effects of trandolapril were investigated in rats with an aortocaval fistula (ACF rats). The aortocaval shunt was created using a needle technique and progression of cardiac remodeling to heart failure was followed for 24 weeks...
2021: Frontiers in Pharmacology
https://read.qxmd.com/read/34421325/repurposing-the-inhibitors-of-covid-19-key-proteins-through-molecular-docking-approach
#15
JOURNAL ARTICLE
Huda Ahmed Alghamdi, Syed Awais Attique, Wei Yan, Anam Arooj, Obaid Albulym, Daochen Zhu, Muhammad Bilal, Muhammad Zohaib Nawaz
The severe acute respiratory syndrome coronavirus 2, famous as COVID-19, has recently emerged as a novel virus and imposed an unrecoverable loss to global health and the economy. At present, no effective drug against COVID-19 is available and currently available viral drugs targeting the viral key proteins of related RNA viruses have been found ineffective against COVID-19. This study evaluated the inhibitors of the viral proteases and other structural proteins, including Mpro (Main protease), RdRp (RNA-dependent RNA polymerase), and spike glycoprotein from synthetic and herbal sources...
November 2021: Process Biochemistry
https://read.qxmd.com/read/34181629/comparison-chart-some-drugs-for-hfref
#16
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
June 14, 2021: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/34181628/drugs-for-chronic-heart-failure
#17
REVIEW
(no author information available yet)
No abstract text is available yet for this article.
June 14, 2021: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/34172790/pulmonary-adverse-drug-event-data-in-hypertension-with-implications-on-covid-19-morbidity
#18
JOURNAL ARTICLE
Majid Jaberi-Douraki, Emma Meyer, Jim Riviere, Nuwan Indika Millagaha Gedara, Jessica Kawakami, Gerald J Wyckoff, Xuan Xu
Hypertension is a recognized comorbidity for COVID-19. The association of antihypertensive medications with outcomes in patients with hypertension is not fully described. However, angiotensin-converting enzyme 2 (ACE2), responsible for host entry of the novel coronavirus (SARS-CoV-2) leading to COVID-19, is postulated to be upregulated in patients taking angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs). Here, we evaluated the occurrence of pulmonary adverse drug events (ADEs) in patients with hypertension receiving ACEIs/ARBs to determine if disparities exist between individual drugs within the respective classes using data from the FDA Spontaneous Reporting Systems...
June 25, 2021: Scientific Reports
https://read.qxmd.com/read/33914047/association-of-1-year-blood-pressure-variability-with-long-term-mortality-among-adults-with-coronary-artery-disease-a-post-hoc-analysis-of-a-randomized-clinical-trial
#19
JOURNAL ARTICLE
Osama Dasa, Steven M Smith, George Howard, Rhonda M Cooper-DeHoff, Yan Gong, Eileen Handberg, Carl J Pepine
Importance: Accumulating evidence indicates that higher blood pressure (BP) variability from one physician office visit to the next (hereafter referred to as visit-to-visit BP variability) is associated with poor outcomes. Short-term measurement (throughout 1 year) of visit-to-visit BP variability in high-risk older patients may help identify patients at increased risk of death. Objective: To evaluate whether short-term visit-to-visit BP variability is associated with increased long-term mortality risk...
April 1, 2021: JAMA Network Open
https://read.qxmd.com/read/33817619/optimal-systolic-blood-pressure-and-reduced-long-term-mortality-in-older-hypertensive-women-with-prior-coronary-events-an-analysis-from-invest%C3%A2
#20
JOURNAL ARTICLE
Ruxandra I Sava, Steven M Smith, Yiqing Chen, Yasmeen Taha, Yan Gong, Ellen C Keeley, Rhonda M Cooper-Dehoff, Carl J Pepine, Eileen M Handberg
Background: Hypertension and coronary artery disease (CAD) are a prevalent combination in older women, however limited data are available to guide blood pressure (BP) management. We hypothesized that older women with hypertension and CAD may not derive long-term benefit by achieving systolic BP (SBP) < 130 mmHg. Methods: We analyzed long-term all-cause mortality data from the International Verapamil SR/Trandolapril Study (INVEST), stratified by risk attributable to clinical severity of CAD (women with prior coronary events of myocardial infarction or revascularization considered high risk, all others at low risk) and by age group (50-64 or ≥65 years)...
December 2020: International Journal of Cardiology. Hypertension
keyword
keyword
27008
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.